A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for their first product launch.
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down in response to changing launch timelines and to balance short- and long-term objectives. With a heavy emphasis on market development, we empowered the client to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
Challenge
Challenge
Challenge
Challenge
+
+
Goals
Goals
A biotech company with expertise in psychiatry needed a flexible partner with the clinical expertise and therapeutic depth necessary to enter the oncology space with a promising immunotherapy candidate.
+
Goals
Goals
We proposed a joint development model with a shared purpose and goals for accelerating development of a key product. Our team – consisting of oncology and operational experts as well as product development strategists -- were fully aligned within the company’s own product development team, creating truly seamless collaboration as we assumed responsibility for delivering their phase I/II clinical studies. This was during the pandemic, and we encouraged the company to move forward even though other companies were choosing to hold back. High levels of recruitment showed how the company became a solution for patients when other sponsors were not. By leveraging Syneos Health strengths to accelerate clinical development and support patients while building a global oncology presence, the company achieved fast track FDA approval and orphan drug designation within two years of our collaboration.
+
Mission
Mission
A small biotech company with a large portfolio of assets and a small number of staff. They wanted to continue maintaining a small staff footprint and low fixed costs while they made go/no-go product development decisions for a group of promising, recently acquired assets.
+
Mission
Mission
We worked with the company to evolve the traditional outsourcing model, assembling teams able to assess and plan for a large number of assets simultaneously. These strong clinical development teams were led by Syneos Health asset strategists – exceptional individuals with a wealth of experience across the product development continuum who understood the company’s mission and culture. The teams conducted expert market analysis and the early-stage clinical trials needed for efficient go/no-go decision-making – thus helping the company conserve its capital for other investments -- and then optimized product development plans for the most promising assets moving forward. These asset teams included Syneos Health operational and therapeutic experts so that there was a seamless transition from asset planning to Phase I-III study execution.
+
Mission
Mission
A small biotech company with a large portfolio of assets and a small number of staff. They wanted to continue maintaining a small staff footprint and low fixed costs while they made go/no-go product development decisions for a group of promising, recently acquired assets.
+
Mission
Mission
We worked with the company to evolve the traditional outsourcing model, assembling teams able to assess and plan for a large number of assets simultaneously. These strong clinical development teams were led by Syneos Health asset strategists – exceptional individuals with a wealth of experience across the product development continuum who understood the company’s mission and culture. The teams conducted expert market analysis and the early-stage clinical trials needed for efficient go/no-go decision-making – thus helping the company conserve its capital for other investments -- and then optimized product development plans for the most promising assets moving forward. These asset teams included Syneos Health operational and therapeutic experts so that there was a seamless transition from asset planning to Phase I-III study execution.
+
Goals
Goals
A biotech company with expertise in psychiatry needed a flexible partner with the clinical expertise and therapeutic depth necessary to enter the oncology space with a promising immunotherapy candidate.
+
Goals
Goals
We proposed a joint development model with a shared purpose and goals for accelerating development of a key product. Our team – consisting of oncology and operational experts as well as product development strategists -- were fully aligned within the company’s own product development team, creating truly seamless collaboration as we assumed responsibility for delivering their phase I/II clinical studies. This was during the pandemic, and we encouraged the company to move forward even though other companies were choosing to hold back. High levels of recruitment showed how the company became a solution for patients when other sponsors were not. By leveraging Syneos Health strengths to accelerate clinical development and support patients while building a global oncology presence, the company achieved fast track FDA approval and orphan drug designation within two years of our collaboration.
+
Challenge
Challenge
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for their first product launch.
+
Challenge
Challenge
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down in response to changing launch timelines and to balance short- and long-term objectives. With a heavy emphasis on market development, we empowered the client to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
+
Mission
Mission
A small biotech company with a large portfolio of assets and a small number of staff. They wanted to continue maintaining a small staff footprint and low fixed costs while they made go/no-go product development decisions for a group of promising, recently acquired assets.
+
Mission
Mission
We worked with the company to evolve the traditional outsourcing model, assembling teams able to assess and plan for a large number of assets simultaneously. These strong clinical development teams were led by Syneos Health asset strategists – exceptional individuals with a wealth of experience across the product development continuum who understood the company’s mission and culture. The teams conducted expert market analysis and the early-stage clinical trials needed for efficient go/no-go decision-making – thus helping the company conserve its capital for other investments -- and then optimized product development plans for the most promising assets moving forward. These asset teams included Syneos Health operational and therapeutic experts so that there was a seamless transition from asset planning to Phase I-III study execution.
+
Goals
Goals
A biotech company with expertise in psychiatry needed a flexible partner with the clinical expertise and therapeutic depth necessary to enter the oncology space with a promising immunotherapy candidate.
+
Goals
Goals
We proposed a joint development model with a shared purpose and goals for accelerating development of a key product. Our team – consisting of oncology and operational experts as well as product development strategists -- were fully aligned within the company’s own product development team, creating truly seamless collaboration as we assumed responsibility for delivering their phase I/II clinical studies. This was during the pandemic, and we encouraged the company to move forward even though other companies were choosing to hold back. High levels of recruitment showed how the company became a solution for patients when other sponsors were not. By leveraging Syneos Health strengths to accelerate clinical development and support patients while building a global oncology presence, the company achieved fast track FDA approval and orphan drug designation within two years of our collaboration.
+
Challenge
Challenge
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for their first product launch.
+
Challenge
Challenge
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down in response to changing launch timelines and to balance short- and long-term objectives. With a heavy emphasis on market development, we empowered the client to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
+
Mission
Mission
A small biotech company with a large portfolio of assets and a small number of staff. They wanted to continue maintaining a small staff footprint and low fixed costs while they made go/no-go product development decisions for a group of promising, recently acquired assets.
+
Mission
Mission
We worked with the company to evolve the traditional outsourcing model, assembling teams able to assess and plan for a large number of assets simultaneously. These strong clinical development teams were led by Syneos Health asset strategists – exceptional individuals with a wealth of experience across the product development continuum who understood the company’s mission and culture. The teams conducted expert market analysis and the early-stage clinical trials needed for efficient go/no-go decision-making – thus helping the company conserve its capital for other investments -- and then optimized product development plans for the most promising assets moving forward. These asset teams included Syneos Health operational and therapeutic experts so that there was a seamless transition from asset planning to Phase I-III study execution.
+
Goals
Goals
A biotech company with expertise in psychiatry needed a flexible partner with the clinical expertise and therapeutic depth necessary to enter the oncology space with a promising immunotherapy candidate.
+
Goals
Goals
We proposed a joint development model with a shared purpose and goals for accelerating development of a key product. Our team – consisting of oncology and operational experts as well as product development strategists -- were fully aligned within the company’s own product development team, creating truly seamless collaboration as we assumed responsibility for delivering their phase I/II clinical studies. This was during the pandemic, and we encouraged the company to move forward even though other companies were choosing to hold back. High levels of recruitment showed how the company became a solution for patients when other sponsors were not. By leveraging Syneos Health strengths to accelerate clinical development and support patients while building a global oncology presence, the company achieved fast track FDA approval and orphan drug designation within two years of our collaboration.
+
Challenge
Challenge
A small to mid-sized biotech with an innovative platform for the development of treatments in oncology but a limited commercial team needed support for their first product launch.
+
Challenge
Challenge
We partnered with the commercial team to provide all commercial launch services, offering crucial global leadership that enabled the team to dynamically scale up and down in response to changing launch timelines and to balance short- and long-term objectives. With a heavy emphasis on market development, we empowered the client to be fully engaged and aligned with all communities and show an in-depth understanding of market dynamics.
+